-
Mashup Score: 1Unlocking Complex Cell-Based Gene Therapies - 2 day(s) ago
0:15 – Meeting Begins3:10 – Opening Keynote from Namandjé Bumpus, U.S. FDA and Peter Marks, CBER, U.S. FDA28:42 – The Evolution of Cell and Gene Therapies: C…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development. However, the heterogeneity in ctDNA levels prior to treatment (baseline) across different cancer types and stages and across ctDNA assays has not been widely studied. Friends of Cancer Research formed a collaboration across multiple commercial ctDNA assay developers to assess baseline ctDNA levels across five cancer types in early- and late-stage disease. This retrospective study included eight commercial ctDNA assay developers providing summary-level de-identified data for patients with non-small cell lung cancer (NSCLC), bladder, breast, prostate, and head and neck squamous cell carcinoma following a common analysis protocol. Baseline ctDNA levels across late-stage cancer types were similarly detected, highlighting the potential use of ctDNA as a biomarker in these cancer types. Variability was observed in ctDNA levels
Source: www.mdpi.comCategories: General Medicine News, Onc News and JournalsTweet-
We are excited to announce a new @CancerResrch publication in @MDPI Journal Diagnostics evaluating ctDNA levels prior to cancer treatment to identify overall trends and considerations to inform the use of #ctDNA in oncology drug development. https://t.co/FNpVn2BWrf #ctDNAFriends https://t.co/W1MfWt9KPY
-
-
Mashup Score: 8
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development. However, the heterogeneity in ctDNA levels prior to treatment (baseline) across different cancer types and stages and across ctDNA assays has not been widely studied. Friends of Cancer Research formed a collaboration across multiple commercial ctDNA assay developers to assess baseline ctDNA levels across five cancer types in early- and late-stage disease. This retrospective study included eight commercial ctDNA assay developers providing summary-level de-identified data for patients with non-small cell lung cancer (NSCLC), bladder, breast, prostate, and head and neck squamous cell carcinoma following a common analysis protocol. Baseline ctDNA levels across late-stage cancer types were similarly detected, highlighting the potential use of ctDNA as a biomarker in these cancer types. Variability was observed in ctDNA levels
Source: www.mdpi.comCategories: General Medicine News, Onc News and JournalsTweet-
We are excited to announce a new @CancerResrch publication in @MDPI Journal Diagnostics evaluating ctDNA levels prior to cancer treatment to identify overall trends and considerations to inform the use of #ctDNA in oncology drug development. https://t.co/FNpVn2BWrf #ctDNAFriends https://t.co/W1MfWt9KPY
-
-
Mashup Score: 8
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development. However, the heterogeneity in ctDNA levels prior to treatment (baseline) across different cancer types and stages and across ctDNA assays has not been widely studied. Friends of Cancer Research formed a collaboration across multiple commercial ctDNA assay developers to assess baseline ctDNA levels across five cancer types in early- and late-stage disease. This retrospective study included eight commercial ctDNA assay developers providing summary-level de-identified data for patients with non-small cell lung cancer (NSCLC), bladder, breast, prostate, and head and neck squamous cell carcinoma following a common analysis protocol. Baseline ctDNA levels across late-stage cancer types were similarly detected, highlighting the potential use of ctDNA as a biomarker in these cancer types. Variability was observed in ctDNA levels
Source: www.mdpi.comCategories: General Medicine News, Onc News and JournalsTweet-
We are excited to announce a new @CancerResrch publication in @MDPI Journal Diagnostics evaluating ctDNA levels prior to cancer treatment to identify overall trends and considerations to inform the use of #ctDNA in oncology drug development. https://t.co/FNpVn2BWrf #ctDNAFriends https://t.co/W1MfWt9KPY
-
-
Mashup Score: 8
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development. However, the heterogeneity in ctDNA levels prior to treatment (baseline) across different cancer types and stages and across ctDNA assays has not been widely studied. Friends of Cancer Research formed a collaboration across multiple commercial ctDNA assay developers to assess baseline ctDNA levels across five cancer types in early- and late-stage disease. This retrospective study included eight commercial ctDNA assay developers providing summary-level de-identified data for patients with non-small cell lung cancer (NSCLC), bladder, breast, prostate, and head and neck squamous cell carcinoma following a common analysis protocol. Baseline ctDNA levels across late-stage cancer types were similarly detected, highlighting the potential use of ctDNA as a biomarker in these cancer types. Variability was observed in ctDNA levels
Source: www.mdpi.comCategories: General Medicine News, Onc News and JournalsTweet-
We are excited to announce a new @CancerResrch publication in @MDPI Journal Diagnostics evaluating ctDNA levels prior to cancer treatment to identify overall trends and considerations to inform the use of #ctDNA in oncology drug development. https://t.co/FNpVn2BWrf #ctDNAFriends https://t.co/W1MfWt9KPY
-
-
Mashup Score: 6The Future of Diagnostic Tests: New Data & Modern Policy - 6 day(s) ago
The Future of Diagnostic Tests: New Data & Modern Policy4:41 – Welcoming Remarks8:57 – Opening Keynote (Jeff Shuren, Director, CDRH, U.S. FDA)35:17 – Sessi…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6The Future of Diagnostic Tests: New Data & Modern Policy - 6 day(s) ago
The Future of Diagnostic Tests: New Data & Modern Policy4:41 – Welcoming Remarks8:57 – Opening Keynote (Jeff Shuren, Director, CDRH, U.S. FDA)35:17 – Sessi…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6The Future of Diagnostic Tests: New Data & Modern Policy - 6 day(s) ago
The Future of Diagnostic Tests: New Data & Modern Policy4:41 – Welcoming Remarks8:57 – Opening Keynote (Jeff Shuren, Director, CDRH, U.S. FDA)35:17 – Sessi…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6The Future of Diagnostic Tests: New Data & Modern Policy - 6 day(s) ago
The Future of Diagnostic Tests: New Data & Modern Policy4:41 – Welcoming Remarks8:57 – Opening Keynote (Jeff Shuren, Director, CDRH, U.S. FDA)35:17 – Sessi…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6The Future of Diagnostic Tests: New Data & Modern Policy - 6 day(s) ago
The Future of Diagnostic Tests: New Data & Modern Policy4:41 – Welcoming Remarks8:57 – Opening Keynote (Jeff Shuren, Director, CDRH, U.S. FDA)35:17 – Sessi…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
Missed our public #CGT meeting with @parkerici “Unlocking Complex Cell-based Gene Therapies” this week? Watch the full event here: https://t.co/tJgEMflBKF